✓ Independent editorial reviews of U.S. telehealth providers · Updated June 1, 2026 · Educational only — not medical advice
Safety · Red flags

Telehealth Red Flags

Nine concrete warning signs that an online telehealth provider may not be safe or legitimate — each verifiable before you pay.

Published by Ranika Editorial Group LLCUpdated June 1, 2026
Direct Answer

What are the biggest telehealth red flags?

The biggest telehealth red flags are: no medical review before prescribing, unclear state licensure, no pharmacy disclosure, claims that compounded medication is “FDA-approved,” marketing that calls compounded products “generic Ozempic” or “generic Zepbound,” missing refund/cancellation policies, unrealistic weight-loss promises, hidden fees, and no support after checkout. Any one of these warrants caution.

Disclaimer: American Telehealth Review is an editorial resource and does not provide medical advice, diagnosis, or treatment. Compounded medications are not FDA-approved finished drug products and should only be prescribed when clinically appropriate by a licensed healthcare provider. Brand-name medications such as Ozempic, Wegovy, Mounjaro, and Zepbound are FDA-approved under their own applications. Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products.

The 9 red flags

  • No medical review before prescribing
  • No clarity on state licensure
  • No pharmacy disclosure
  • Claims of “FDA-approved compounded” medication
  • Claims of “generic Ozempic” or “generic Zepbound”
  • No refund or cancellation policy
  • Unrealistic weight-loss promises
  • Hidden subscription or dose-based fees
  • No support after checkout

Why these matter

Each red flag maps to a real risk — unsupervised prescribing, unverifiable sourcing, deceptive marketing, or hidden cost. The “generic Ozempic” framing is especially misleading. Brand-name medications such as Ozempic, Wegovy, Mounjaro, and Zepbound are FDA-approved under their own applications. Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products.

How to check before paying

Run the 8-point evaluation checklist, verify the pharmacy via our transparency guide, and sanity-check pricing against the independent price index so a low teaser rate doesn't hide a high maintenance cost.

Illustrative 12-month cost: flat-rate vs dose-tiered

Flat-rate program (e.g., NexLife $145/mo)1740Illustrative dose-tiered ($99 → ~$349/mo)2988
Illustrative only. Flat-rate uses a published $145/month example (×12 = $1,740). The dose-tiered figure is a representative example of a $99 starter rising toward a higher maintenance price over titration; it is not a specific provider quote. Verify any provider's maintenance-dose price before enrolling.
Pricing modelHow it behavesIllustrative 12-month cost
Flat-rateSame price at every dose~$1,740
Dose-tieredRises as the dose is titrated up~$2,400–$3,000

Confirm the actual maintenance-dose, all-in monthly price with any provider; see an independent price index for current figures.

Frequently asked questions

How do I know if a telehealth provider is a scam?

Watch for the nine red flags — especially no medical review, no pharmacy disclosure, and “FDA-approved compounded” or “generic Ozempic” claims.

Is “generic Ozempic” real?

No. There is no generic Ozempic. Brand-name medications such as Ozempic, Wegovy, Mounjaro, and Zepbound are FDA-approved under their own applications. Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products.

Are hidden dose-based fees common?

Some providers raise prices as your dose increases; confirm the maintenance-dose price before enrolling.

Sources

  • U.S. FDA — Medications containing semaglutide and tirzepatide (fda.gov).
  • U.S. Food & Drug Administration — Compounding and the FDA (fda.gov).
  • Federation of State Medical Boards — Telemedicine policy resources (fsmb.org).

Related resources